Bria Cell Therapeutics Corp. BCTX
We take great care to ensure that the data presented and summarized in this overview for BriaCell Therapeutics Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BCTX
View allLatest Institutional Activity in BCTX
Top Purchases
Top Sells
About BCTX
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Insider Transactions at BCTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 14
2024
|
Marc Lustig Director |
BUY
Open market or private purchase
|
Indirect |
902,935
+26.2%
|
$1,805,870
$2.21 P/Share
|
|
Dec 28
2022
|
Jamieson Bondarenko Chairman |
BUY
Open market or private purchase
|
Direct |
28,000
+14.15%
|
$112,000
$4.58 P/Share
|
|
Dec 20
2022
|
Jamieson Bondarenko Chairman |
BUY
Open market or private purchase
|
Direct |
22,000
+13.43%
|
$110,000
$5.35 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 903K shares |
|---|